ArticleScientific reports2025
Induction and characterization of oral submucous fibrosis model with different pathological stages in rats and mice.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Assessment of In Vitro Antioxidant Activity and Subacute Toxicity and Safety of Tetrahydroserpentine in Hyperglycemic Mice.Chemistry & biodiversity · 2026Article
- An organoid-guided roadmap for precision delivery of epigallocatechin gallate in oral submucous fibrosis.Frontiers in bioengineering and biotechnology · 2026Review
- Construction and evaluation of a combined model of NAA/STZ-induced type 2 diabetes with carotid balloon injury in SD rats.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Oral submucous fibrosis (OSF) is a chronic and progressive fibrosis disease. Although its pathological stages are well characterized in clinical settings, corresponding animal models remain lacking, which has significantly hindered in-depth mechanistic studies and the development of targeted interventions. Herein, we developed new methods in creating OSF models in rats and mice by different injection frequency of bleomycin (BLM) to simulate early and middle stages of fibrosis. The results showed both low-frequency (once a week) and high-frequency (twice a week) of injection can cause significant fibrosis characteristics, including mucosal pallor, limitation of mouth opening, collagen deposition and inflammatory response. Histological and molecular analyses confirm the stage-dependent pathological changes. Furthermore, to validate the pathological relevance of the model, human oral mucosal tissues from OSF patients and healthy individuals were also analyzed. The result exhibits that, compared with low-frequency injections, high-frequency injections of BLM can lead to more serious fibrosis and inflammatory responses in rats and mice, which are corresponding with the early and middle characteristics of human OSF. This work developed stable and repeatable OSF models of rats and mice in different pathological stages, which offer valuable tools for mechanistic studies of OSF and further precise stage-specific therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.